NASDAQ:IMRX Immuneering (IMRX) Stock Price, News & Analysis → Elon’s New A.I. Device is About to Shock the World (From InvestorPlace) (Ad) Free IMRX Stock Alerts $1.44 -0.03 (-2.04%) (As of 03:52 PM ET) Add Compare Share Share Today's Range$1.38▼$1.5350-Day Range$1.43▼$6.7652-Week Range$1.38▼$11.92Volume500,116 shsAverage Volume559,762 shsMarket Capitalization$42.70 millionP/E RatioN/ADividend YieldN/APrice Target$13.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Immuneering alerts: Email Address Immuneering MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside812.2% Upside$13.50 Price TargetShort InterestHealthy13.23% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$3.05 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.89) to ($1.86) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.15 out of 5 starsMedical Sector156th out of 904 stocksPharmaceutical Preparations Industry57th out of 421 stocks 4.3 Analyst's Opinion Consensus RatingImmuneering has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 4 buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageImmuneering has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted13.23% of the float of Immuneering has been sold short.Short Interest Ratio / Days to CoverImmuneering has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in Immuneering has recently decreased by 5.21%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldImmuneering does not currently pay a dividend.Dividend GrowthImmuneering does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IMRX. Previous Next 2.2 News and Social Media Coverage News SentimentImmuneering has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.34 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Immuneering this week, compared to 2 articles on an average week.Search InterestOnly 11 people have searched for IMRX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 6 people have added Immuneering to their MarketBeat watchlist in the last 30 days. This is a decrease of -57% compared to the previous 30 days. Previous Next 5.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Immuneering insiders have sold 1,045.28% more of their company's stock than they have bought. Specifically, they have bought $266,645.00 in company stock and sold $3,053,819.00 in company stock.Percentage Held by Insiders23.00% of the stock of Immuneering is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions67.65% of the stock of Immuneering is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Immuneering are expected to grow in the coming year, from ($1.89) to ($1.86) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Immuneering is -0.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Immuneering is -0.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmuneering has a P/B Ratio of 0.48. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceElon’s New A.I. Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” Click here to see the details because there’s a lot of money at stake. About Immuneering Stock (NASDAQ:IMRX)Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.Read More IMRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IMRX Stock News HeadlinesApril 5, 2024 | insidertrades.comCormorant Asset Management, Lp Sells 400,000 Shares of Immuneering Co. (NASDAQ:IMRX) StockApril 17, 2024 | msn.comImmuneering (IMRX) Price Target Decreased by 11.43% to 13.55April 29, 2024 | InvestorPlace (Ad)Elon’s New A.I. Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” April 11, 2024 | investing.comImmuneering advances pancreatic cancer treatment trialApril 9, 2024 | finanznachrichten.deImmuneering Corporation: IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer ModelsApril 9, 2024 | globenewswire.comIMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer ModelsApril 3, 2024 | globenewswire.comImmuneering to Participate in the 23rd Annual Needham Virtual Healthcare ConferenceMarch 29, 2024 | markets.businessinsider.comBuy Rating Affirmed for Immuneering on Solid Trial Progress and Insider ConfidenceApril 29, 2024 | InvestorPlace (Ad)Elon’s New A.I. Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” March 27, 2024 | globenewswire.comImmuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS MutationsMarch 21, 2024 | investing.comImmuneering CEO acquires $55.3k in company stockMarch 21, 2024 | finance.yahoo.comImmuneering Director Acquires 7.5% More StockMarch 18, 2024 | msn.comImmuneering stock rebounds 34% following last week's selloffMarch 18, 2024 | benzinga.comWhy Science Applications International Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Monday's Mid-Day SessionMarch 18, 2024 | msn.comCanopy Growth, Outlook Therapeutics, Immuneering among healthcare moversMarch 15, 2024 | msn.comU.S. shares lower at close of trade; Dow Jones Industrial Average down 0.49%March 15, 2024 | markets.businessinsider.comImmuneering: Hold Rating Amidst Potential and Uncertainties in Drug EfficacyMarch 15, 2024 | markets.businessinsider.comCancer Treatment Focused Immuneering Faces Analyst Downgrades, Who Cite Underwhelming Solid Tumor Trial DataMarch 14, 2024 | benzinga.comWhy Limbach Holdings Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Thursday's Mid-Day SessionMarch 14, 2024 | msn.comWhat's Going On With Cancer-Focused Immuneering Stock On Thursday?March 14, 2024 | markets.businessinsider.comImmuneering IMM-1-104 Trial In RAS-Mutant Solid Tumors Shows Positive Results; Stock UpMarch 14, 2024 | globenewswire.comImmuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid TumorsMarch 13, 2024 | finanznachrichten.deImmuneering Corporation: Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid TumorsMarch 12, 2024 | finance.yahoo.comImmuneering Appoints Thomas J. Schall, Ph.D. to its Board of DirectorsMarch 12, 2024 | globenewswire.comImmuneering Appoints Thomas J. Schall, Ph.D.March 11, 2024 | markets.businessinsider.comImmuneering’s IMM-1-104 Progress Garners Buy Rating Amid Favorable Phase 2 Dose Determination and Anticipated Phase 1 DataMarch 11, 2024 | globenewswire.comImmuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid TumorsSee More Headlines Receive IMRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immuneering and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/01/2024Today4/29/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:IMRX CUSIPN/A CIK1790340 Webwww.immuneering.com Phone617-500-8080FaxN/AEmployees68Year FoundedN/APrice Target and Rating Average Stock Price Target$13.50 High Stock Price Target$25.00 Low Stock Price Target$3.00 Potential Upside/Downside+812.2%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($1.89) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-53,470,000.00 Net MarginsN/A Pretax Margin-5,163,499.50% Return on Equity-52.49% Return on Assets-47.63% Debt Debt-to-Equity RatioN/A Current Ratio11.35 Quick Ratio11.35 Sales & Book Value Annual Sales$320,000.00 Price / Sales137.13 Cash FlowN/A Price / Cash FlowN/A Book Value$3.09 per share Price / Book0.48Miscellaneous Outstanding Shares29,650,000Free Float22,833,000Market Cap$43.88 million OptionableNot Optionable Beta-0.89 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. Benjamin J. Zeskind M.B.A. (Age 42)Ph.D., Co-Founder, President, CEO & Director Comp: $898.42kMr. Robert J. Carpenter M.B.A. (Age 78)M.S., Co-Founder & Chair Emeritus Comp: $83.17kDr. Brett M. Hall Ph.D. (Age 56)Chief Scientific Officer Comp: $867.92kMs. Mallory Morales CPA (Age 40)Principal Financial & Accounting Officer, Chief Accounting Officer and Treasurer Ms. Paula George CPADirector of Accounting & Operations and Assistant Corporate ControllerMr. Michael D. Bookman J.D. (Age 36)Chief Legal Officer & Secretary Ms. Leah R. Neufeld (Age 52)Chief People Officer Dr. Peter King Ph.D.Head of Discovery & VPDr. Praveen Nair Ph.D.Head of Translational Pharmacology & VPMr. Harold E. Brakewood (Age 59)Chief Business Officer More ExecutivesKey CompetitorsJaguar HealthNASDAQ:JAGXCalciMedicaNASDAQ:CALCNabriva TherapeuticsNASDAQ:NBRVAadi BioscienceNASDAQ:AADIRockwell MedicalNASDAQ:RMTIView All CompetitorsInsiders & InstitutionsCormorant Asset Management, LpSold 400,000 sharesTotal: $1.16 M ($2.90/share)Peter FeinbergBought 25,000 shares on 3/22/2024Total: $63,750.00 ($2.55/share)Harold Eugene BrakewoodBought 3,900 shares on 3/22/2024Total: $10,023.00 ($2.57/share)Mallory MoralesBought 1,107 shares on 3/21/2024Total: $3,011.04 ($2.72/share)Leah R NeufeldBought 3,818 shares on 3/20/2024Total: $10,995.84 ($2.88/share)View All Insider TransactionsView All Institutional Transactions IMRX Stock Analysis - Frequently Asked Questions Should I buy or sell Immuneering stock right now? 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Immuneering in the last twelve months. There are currently 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" IMRX shares. View IMRX analyst ratings or view top-rated stocks. What is Immuneering's stock price target for 2024? 8 brokers have issued 1-year target prices for Immuneering's stock. Their IMRX share price targets range from $3.00 to $25.00. On average, they predict the company's stock price to reach $13.50 in the next year. This suggests a possible upside of 812.2% from the stock's current price. View analysts price targets for IMRX or view top-rated stocks among Wall Street analysts. How have IMRX shares performed in 2024? Immuneering's stock was trading at $7.35 at the beginning of 2024. Since then, IMRX shares have decreased by 79.9% and is now trading at $1.48. View the best growth stocks for 2024 here. Are investors shorting Immuneering? Immuneering saw a drop in short interest during the month of April. As of April 15th, there was short interest totaling 2,730,000 shares, a drop of 5.2% from the March 31st total of 2,880,000 shares. Based on an average daily volume of 677,400 shares, the short-interest ratio is presently 4.0 days. Approximately 13.2% of the company's stock are short sold. View Immuneering's Short Interest. When is Immuneering's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our IMRX earnings forecast. How were Immuneering's earnings last quarter? Immuneering Co. (NASDAQ:IMRX) released its quarterly earnings results on Friday, March, 1st. The company reported ($0.52) earnings per share for the quarter, missing analysts' consensus estimates of ($0.46) by $0.06. When did Immuneering IPO? Immuneering (IMRX) raised $105 million in an initial public offering (IPO) on Friday, July 30th 2021. The company issued 7,000,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, Jefferies, Cowen and Guggenheim Securities acted as the underwriters for the IPO. How do I buy shares of Immuneering? Shares of IMRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:IMRX) was last updated on 4/29/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe #1 Biotech Stock to Have on Your Radar in 2024… Huge AlertsAI finds its first serious applicationWall Street StarThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe A.I. story nobody is telling you (Read ASAP)TradeSmith Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immuneering Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
